ENTXEntera Bio Ltd

Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Entera Bio in a research report issued to clients and investors on Monday, April 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0...

HC Wainwright lowered their price objective on shares of Entera Bio from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday...

Entera Bio (NASDAQ:ENTX) executives and physician panelists used a roundtable discussion to highlight what they described as persistent gaps in osteoporosis care and the potential role for the...

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 175,306 shares, a growth of 27.2% from the March 15th total of 137,789 shares. Currently, 0.4% of the shares of the...

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners...

U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchmark indices were higher after they entered the correction territory last week, falling more than 10% below their 52-week highs.read more...

U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchmark indices were higher after they entered the correction territory last week, falling more than 10...

U.S. stock futures up, focus on quarterly earnings of Americas Gold and Silver, ARKO Petroleum, Entera Bio, Phreesia, and Progress Software.read more...